Found: 12
Select item for more details and to access through your institution.
Distinct signatures of host-microbial meta-metabolome and gut microbiome in two C57BL/6 strains under high-fat diet.
- Published in:
- ISME Journal: Multidisciplinary Journal of Microbial Ecology, 2014, v. 8, n. 12, p. 2380, doi. 10.1038/ismej.2014.79
- By:
- Publication type:
- Article
Combining metabolomic non-targeted GC×GC-ToF-MS analysis and chemometric ASCA-based study of variances to assess dietary influence on type 2 diabetes development in a mouse model.
- Published in:
- Analytical & Bioanalytical Chemistry, 2015, v. 407, n. 1, p. 343, doi. 10.1007/s00216-014-8227-4
- By:
- Publication type:
- Article
Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal‐related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 4, p. 599, doi. 10.1111/dom.13935
- By:
- Publication type:
- Article
Impact of insulin glargine and lixisenatide on β-cell function in patients with type 2 diabetes mellitus: A randomized open-label study.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 11, p. 1625, doi. 10.1111/dom.12968
- By:
- Publication type:
- Article
Basal rate tests (24-hour fasts) performed in type-1 diabetic subjects with either absolute fasting or snacks containing negligible carbohydrate amounts result in similar glucose profiles: A randomized controlled prospective trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 6, p. 783, doi. 10.1111/dom.12868
- By:
- Publication type:
- Article
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 3, p. 336, doi. 10.1111/dom.12824
- By:
- Publication type:
- Article
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 2, p. 200, doi. 10.1111/dom.12802
- By:
- Publication type:
- Article
A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.
- Published in:
- Diabetes, Obesity & Metabolism, 2017, v. 19, n. 2, p. 216, doi. 10.1111/dom.12804
- By:
- Publication type:
- Article
Feedback suppression of meal-induced glucagon-like peptide-1 ( GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
- Published in:
- Diabetes, Obesity & Metabolism, 2016, v. 18, n. 11, p. 1100, doi. 10.1111/dom.12706
- By:
- Publication type:
- Article
The impact of blood on liver metabolite profiling - a combined metabolomic and proteomic approach.
- Published in:
- Biomedical Chromatography, 2014, v. 28, n. 2, p. 231, doi. 10.1002/bmc.3010
- By:
- Publication type:
- Article
Importance of localization of insulinomas: a systematic analysis.
- Published in:
- Journal of Hepato -- Biliary -- Pancreatic Sciences, 2019, v. 26, n. 9, p. 383, doi. 10.1002/jhbp.642
- By:
- Publication type:
- Article
Irp2 regulates insulin production through iron-mediated Cdkal1-catalyzed tRNA modification.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-019-14004-5
- By:
- Publication type:
- Article